UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis
· ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase 3 studies · AD is the most common chronic inflammatory skin disease in the developed world · Orismilast is a next generation PDE4 inhibitor shown to be potent in inhibiting pathways important in AD · Orismilast MR tablet is also in development for the treatment of psoriasis and hidradenitis suppurativa (HS) Hellerup, Denmark, 4 August 2022 – UNION therapeutics A/S (UNION), a